Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Buys Bigger Stake in BioSource After Firm Rejected Earlier Acquisition Offer

NEW YORK, April 19 (GenomeWeb News) - After BioSource International rebuffed Bio-Rad's recent unsolicited $82 million acquisition offer, Bio-Rad today said it has increased its ownership in the reagents company to 6.8 percent from 5 percent.

Illustrating what it calls its "continuing interest" in acquiring the company, Bio-Rad disclosed in an SEC filing today that it has purchased approximately $4.97 million worth of additional shares of BioSource common stock. In the filing, Bio-Rad stated that it believed "ownership of the shares could facilitate a business combination between [BioSource] and Bio-Rad."

"Our purchase of additional shares in BioSource further demonstrates our continuing interest in acquiring this company," Norman Schwartz, Bio-Rad's president, said in a statement today. "Including these recent stock purchases, the average price for the shares we have acquired to date is still well below our $8.50 per share offer."

Earlier this month, BioSource's directors unanimously rejected Bio-Rad's $82 million offer to purchase the company, stating that they believed Bio-Rad's April 6 offer of $8.50 per share was "significantly below BioSource's inherent value."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.